Investigational drug · Phase 3
Crofelemer for
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
15
Any phase or sponsor naming "Crofelemer for"
First trial start
2025
May 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Crofelemer for", any sponsor or status.
Conditions studied
As listed on its trial records.
- Microvillus Inclusion Disease
- Congenital Disorders
- Rare Diseases
- Short Bowel Syndrome
- Malabsorption Syndromes
- Short Gut Syndrome
- Post-Op Complication
- Functional Gastrointestinal Disorders
Approved drugs for the same conditions: Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Crofelemer for" as an intervention, largest first.
Shaman PharmaceuticalsIndustry
NCT00002186 · 400 participants
Drug: Crofelemer; Acyclovir · For: Herpes Simplex; HIV Infections
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 34 sites in all
- Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated DiarrheaPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00547898 · 374 participants · Start Oct 2007 · Primary completion Jan 27, 2011
Drug: Crofelemer 125 mg; Crofelemer 250 mg and 2 more · For: HIV Associated Diarrhea
Sites: Huntsville, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 82 sites in all
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) PatientsPivotal-lookingCompleted
Shaman PharmaceuticalsIndustry
NCT00002408 · 300 participants
Drug: Crofelemer · For: Diarrhea; HIV Infections
Sites: Scottsdale, Arizona; Los Angeles, California; Palo Alto, California · 36 sites in all
- Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer TherapyPivotal-lookingCompleted
Napo Pharmaceuticals, Inc.Industry
NCT04538625 · 287 participants · Start Oct 7, 2020 · Primary completion Aug 7, 2023
Drug: Crofelemer 125 MG [Mytesi]; Placebo · For: Cancer Therapy-Related Diarrhea; Chemotherapy-related Diarrhea; Adult Solid Tumor and 3 more
Sites: Prescott, Arizona; Anaheim, California; Corona, California · 52 sites in all
- Safety and Tolerability of Crofelemer for HIV-Associated DiarrheaPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01374490 · 250 participants · Start Jun 7, 2011 · Primary completion Oct 31, 2012
Drug: Crofelemer · For: HIV Enteropathy; Diarrhea With HIV
Sites: Phoenix, Arizona; Little Rock, Arkansas; Bakersfield, California · 21 sites in all
- A Study of Crofelemer to Treat Diarrhea Irritable Bowel SyndromePivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00101725 · 245 participants · Start Dec 2004 · Primary completion Nov 2005
Drug: crofelemer · For: Irritable Bowel Syndrome; Colonic Diseases; Diarrhea and 1 more
Sites: Huntsville, Alabama; Chandler, Arizona; North Little Rock, Arkansas · 29 sites in all
- Diarrhea Predominant Irritable Bowel Syndrome in FemalesPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT00461526 · 240 participants · Start Oct 2006 · Primary completion Dec 2007
Drug: crofelemer · For: Irritable Bowel Syndrome
Sites: Huntsville, Alabama; Chandler, Arizona; Tucson, Arizona · 43 sites in all
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03898856 · 93 participants · Start Apr 1, 2019 · Primary completion Jan 30, 2025
Drug: Crofelemer · For: Chronic Diarrhea of Unknown Origin
Sites: Houston, Texas
- Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer PatientsCompleted
Sandra SwainAcademic, hospital or other
NCT02910219 · 53 participants · Start Jan 31, 2017 · Primary completion Nov 23, 2020
Drug: Crofelemer · For: Breast Cancer
Sites: Washington D.C., District of Columbia; Baltimore, Maryland; Hackensack, New Jersey · 4 sites in all
Napo Therapeutics, S.p.A.Industry
NCT06904872 · 18 participants (planned) · Start May 29, 2025 · Primary completion Mar 2027
Drug: Crofelemer Powder for Oral Solution; Matched Placebo Powder for Oral Solution · For: Short Bowel Syndrome; Malabsorption Syndromes; Short Gut Syndrome and 2 more
Sites: Aachen, Germany; Berlin, Germany; Essen, Germany · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.